Wall Street’s Top Analysts Upgrades, Downgrades & Initiations

Wall Street’s Top Analysts Upgrades, Downgrades & Initiations


Daily HeffX-LTN reviews Wall Street analysts research reports to find new investing and trading ideas for our readers. Some reports cover stocks to buy, and others cover stocks to sell or avoid.

Below is a list of Wall Street’s Top analysts outlook for Key issues for Thursday, as follows:

Abercrombie & Fitch Co. (NYSE:ANF) was reiterated as Buy and with a 25 target price at Argus. The independent research firm had just raised its rating to Buy in January.

Altria Group Inc. (NYSE:MO) was reiterated as Buy with a 79 price target at Argus. The firm sees Altria continuing to diversify away from tobacco risks with non-tobacco efforts, and it raised Y 2018 earnings to 4.00 from 3.59/share and set a 4.38 per share target for Y 2019.

Bluebird Bio Inc. (NASDAQ:BLUE) was started with a Neutral rating and given a 220 fair value estimate at Janney.

Century Aluminum Co. (NASDAQ:CENX) was raised to Overweight from Neutral with a 29 price target at JPMorgan. This is after Cowen and BMO upgraded it earlier this week.

Cornerstone OnDemand Inc. (NASDAQ:CSOD) was reiterated as Outperform and the price target was raised to 51 from 49 at Credit Suisse.

Epizyme Inc. (NASDAQ:EPZM) was maintained as Outperform but the price target was cut to 25 from 26 at Oppenheimer. Wedbush maintained its Outperform rating and raised its target to 24 from 21 after incorporating its mesothelioma opportunity into the model.

Ford Motor Co. (NYSE:F) was raised to Overweight from Underweight with a 15 price target at Morgan Stanley.

Stay tuned…

The following two tabs change content below.

Paul Ebeling

Paul A. Ebeling, polymath, excels in diverse fields of knowledge. Pattern Recognition Analyst in Equities, Commodities and Foreign Exchange and author of “The Red Roadmaster’s Technical Report” on the US Major Market Indices™, a highly regarded, weekly financial market letter, he is also a philosopher, issuing insights on a wide range of subjects to a following of over 250,000 cohorts. An international audience of opinion makers, business leaders, and global organizations recognizes Ebeling as an expert.

You must be logged in to post comments :